Affymetrix, Inc. (NASDAQ:AFFX) Signs Multi-year Supply Agreement With Ariosa Diagnostics, Inc.

Affymetrix, Inc. (NASDAQ:AFFX) has signed a multi-year supply agreement with Ariosa Diagnostics, Inc. The agreement is made in support of non-invasive prenatal test of Ariosa. The arrays and instruments of Affymetrix will be utilized in Ariosa’s non-invasive prenatal test. Ariosa can start working on Harmony test kit encouraging other laboratories across the world for the same process.

The Harmony test

It is a form of prenatal non-invasive blood test for women. The experts evaluate cell-free DNA in maternal blood. The test is meant to assess the risk of Down syndrome in the fetus. The test is available in more than ninety countries.

The follow-up

Recently, a study was published in Fetal Diagnosis and Therapy online showing that Ariosa’s scientists have received success in testing and implementing microarrays of Affymetrix, Inc. (NASDAQ:AFFX) as a part of a DNA quantification technique for the Harmony test. The published study stated that Affymetrix microarrays performed much better compared to next-generation sequencing approach. The performance was measured in terms of improved precision and shorter turn-around time while measuring fetal fraction and chromosome concentration levels of cell-free DNA.

The management view

Ken Song, the CEO of Ariosa, said that it is an exciting moment to form partnership with a reliable and robust supplier like Affymetrix. The microarray inclusion opens up new opportunities to work use kit decentralization strategy for the further development of Harmony test. it will result in enhanced prenatal care for women across the world.

The partnership

Ariosa and Affymetrix are partners in the innovative Affymetrix Program. The assay and array technologies form the main base of genomic tools in oncology and reproductive health applications. There is a need of innovative solutions for many problems in the medical field. Affymetrix, Inc. (NASDAQ:AFFX) is working in mutual association with Ariosa as its instrumentation and arrays will prove beneficial in the fulfillment of global business strategy.

About the Author

Laurie, a long-time member of the US Markets Daily general assignment reporter who has covered a variety of subjects from breaking news to investigative features, from stock markets to politics, and from neighborhood small business to global warming.

Leave A Response